CN1075633A - 脂质体炎痛喜康制剂 - Google Patents
脂质体炎痛喜康制剂 Download PDFInfo
- Publication number
- CN1075633A CN1075633A CN93101515A CN93101515A CN1075633A CN 1075633 A CN1075633 A CN 1075633A CN 93101515 A CN93101515 A CN 93101515A CN 93101515 A CN93101515 A CN 93101515A CN 1075633 A CN1075633 A CN 1075633A
- Authority
- CN
- China
- Prior art keywords
- compositions
- phospholipid
- piroxicam
- amount
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 229960002702 piroxicam Drugs 0.000 title claims abstract description 33
- 238000009472 formulation Methods 0.000 title claims abstract description 21
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 30
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 claims description 30
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 20
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000002502 liposome Substances 0.000 claims description 11
- 235000012000 cholesterol Nutrition 0.000 claims description 10
- 239000000232 Lipid Bilayer Substances 0.000 claims description 8
- 239000002562 thickening agent Substances 0.000 claims description 8
- 230000002421 anti-septic effect Effects 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 6
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 6
- 229960002216 methylparaben Drugs 0.000 claims description 6
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 5
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 5
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 5
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 5
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 5
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 5
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000003792 electrolyte Substances 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 230000007928 solubilization Effects 0.000 claims description 2
- 238000005063 solubilization Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 9
- 239000000654 additive Substances 0.000 description 8
- 230000000996 additive effect Effects 0.000 description 7
- 229940107161 cholesterol Drugs 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- -1 ascorbinstearate Substances 0.000 description 4
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 229940083466 soybean lecithin Drugs 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000026137 Soft tissue injury Diseases 0.000 description 2
- 208000010040 Sprains and Strains Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 210000000323 shoulder joint Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000007516 brønsted-lowry acids Chemical class 0.000 description 1
- 150000007528 brønsted-lowry bases Chemical class 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000003797 carpal joint Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- BEGBSFPALGFMJI-UHFFFAOYSA-N ethene;sodium Chemical group [Na].C=C BEGBSFPALGFMJI-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- LZFIOSVZIQOVFW-UHFFFAOYSA-N propyl 2-hydroxybenzoate Chemical compound CCCOC(=O)C1=CC=CC=C1O LZFIOSVZIQOVFW-UHFFFAOYSA-N 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供了包含炎痛喜康、磷脂、供炎痛喜康
和所述磷脂用的溶剂体系、水和常规的辅助配制剂的
局部用脂质体制剂,及所述制剂的制造方法。
Description
本发明涉及包含炎痛喜康、磷脂、供炎痛喜康和所述磷脂用的溶剂体系、水和常规辅助配制剂的局部用脂质体制剂及其制备方法。
JP-61/172,833公开了包含非甾族抗炎药如消火痛和炎痛喜康与磷脂的制剂。但是,所述组合物不是由脂质体构成的。EP-0,249,561和EP-0,260,241公开了供包括炎痛喜康在内的活性成分全身给药的特殊的脂质体制剂。EP-0,253,619描述了一种常规的制备含有包封的活性成分的单一双层脂质体的制备方法。
炎痛喜康是一种止痛、抗炎和解热的药物,它微溶于水和/或醇介质中。该性质极大地妨碍了有效的局部用炎痛喜康制剂的形成。为了将足够量的活性成分输送到所治疗区域,经典的局部用制剂通常含有相当大量的几乎全部分散的炎痛喜康。通过使用一种专门设计的有机溶剂体系现已解决了该问题。
本发明脂质体炎痛喜康制剂迅速地并深深地渗透到上皮组织中,表现出优良的活性组分在其中的保留性。虽然本发明制剂中炎痛喜康的浓度通常比其中分散有炎痛喜康的经典的乳油制剂中炎痛喜康的浓度低得多,但其效力与所述的经典乳油制剂相似。本发明的制剂稳定,特别是没有微溶活性组分炎痛喜康发生结晶的缺点。
本发明提供了包含炎痛喜康、磷脂、供炎痛喜康和所述磷脂用的溶剂体系、水和常规的辅助配制剂的局部用脂质体制剂,其特征在于所述组合物包含二甲基异山梨糖醇酐(dimethylisosorbide)和四甘醇作为溶剂体系。所述溶剂体系在局部用脂质体制剂中的应用是新的。
本发明组合物优选为单一双层脂质体形式,特别是大小为100-1000nm,更特别是100-500nm的脂质体形式。一般来说,脂质体制剂的稳定性随单一双层脂质体的大小减小而增强。单一双层脂质体亦称作单片囊,由合适的双亲和性分子如磷脂的单一双层构成,双亲和性分子包封水相,被水相相互分离。
下文中,本发明组合物中各组分的量以基于制剂的总重量的重量百分比表示。相似地,比率为重量比率。
合适的用于本发明组合物中的磷脂有,例如,磷脂酰胆碱、乙醇胺和丝氨酸、鞘磷脂、心磷脂、缩醛磷脂、磷脂酸和脑苷脂类,特别是那些可与炎痛喜康一起溶于无毒的、可药用的有机溶剂中的磷脂。优选的磷脂有,例如,磷脂酰胆碱、磷脂酰乙醇胺、磷脂酰丝氨酸、磷脂酰肌醇、溶血磷脂酰胆碱、磷脂酰甘油等,以及它们的混合物,尤其是卵磷脂如大豆卵磷脂。磷脂在本发明组合物中的用量可为大约10%至大约30%,优选大约15%至大约25%,尤其是大约20%。
有利地,可以使用亲脂性添加剂来选择性地改进脂质体的特性。这样的添加剂的实例包括,例如,硬脂胺(stearylamine)、磷脂酸,生育酚、胆固醇、胆固醇半琥珀酸酯和羊毛脂提取物;优选的亲脂性添加剂是胆固醇。亲脂性添加剂的用量可是0.5-8%,优选1.5-4%,特别是大约2%。通常,亲脂性添加剂的量与磷脂的量的比率范围为大约1∶8至大约1∶12,特别是大约1∶10。
所述的磷脂、亲脂性添加剂和活性组分炎痛喜康与可溶解所述诸组分的无毒的可药用的有机溶剂体系结合使用。用于本发明制剂中的有机溶剂体系极其重要。所述溶剂体系不仅必须完全溶解活性组分炎痛喜康,而且也必须能形成稳定的单一双层脂质体。所述溶剂体系包含大约8%至大约30%、特别是大约12%至大约20%、最好是大约15%的二甲基异山梨糖醇酐和四甘醇(糖糠醛(glycofurol)、四氢糖醇聚乙二醇醚)。在所述溶剂体系中,二甲基异山梨糖醇酐的量与四甘醇的量的比率范围可以为大约2∶1至大约1∶3,特别是大约1∶1至大约1∶2.5,最好是大约1∶2。这样,在最终组合物中四甘醇量可在5-20%之间变化,特别是5-15%,最好是大约10%。在最终组合物中二甲基异山梨糖醇酐的量可为3-10%,特别是3-7%,最好是大约5%。
下文中所用的术语“有机组分”是指包括所述磷脂、亲脂性添加剂和有机溶剂的混合物。
将活性组分炎痛喜康溶解于有机组分中。使用微粉化形式的活性组分以促进溶解可能是有利的。最终制剂中活性组分的量为0.1-0.6%,特别是0.4-0.5%,最好是大约0.5%。此外,也可以向有机组分中加入其他组分如抗氧化剂。其他组分的实例包括生育酚、丁化羟基茴香醚、丁化羟基甲苯、抗坏血酸棕榈酸脂、抗坏血酸油酸酯等。
本发明制剂中的水相组分主要包括水,可以含有各种添加剂如电解质、缓冲体系、防腐剂等。合适的电解质包括金属盐,特别是碱金属和碱土金属盐如氯化钙、氯化钠、氯化钾,优选氯化钠。电解质的浓度可以在很宽范围内变化,取决于最终制剂中各组分的性质和浓度,并且应足以稳定脂质体膜。在本发明的组合物中,氯化钠的量可为0.05-0.2%,特别是约0.1%。缓冲体系包括适量的酸如磷酸、琥珀酸、或最好是柠檬酸和碱、特别是氢氧化钠的混合物。所述缓冲体系应保持制剂的pH为5-7,优选5-6.5,尤其是5.5-6。可用于本发明组合物中来防止微生物降解的防腐剂包括苯甲酸、对羟基苯甲酸甲酯和对羟基苯甲酸丙酯。优选地,对羟基苯甲酸甲酯和对羟基-苯甲酸丙酯的用量分别大约为0.2%和0.02%。特别有利的是向水相组分中加入螯合剂如乙二胺四乙酸钠或二钠以防止最终制剂中的磷脂被金属离子氧化降解。例如乙二胺四乙酸二钠的有效量为0.05%-0.25%,特别是大约0.15%。
优选的组合物基于组合物的总重量按重量计包含:
(a)0.1-0.6%炎痛喜康;
(b)10-30%磷脂;
(c)0.5-8%胆固醇;
(d)3-10%二甲基异山梨糖醇酐;
(e)5-20%四甘醇;
(f)保持组合物的pH值在5-7的缓冲剂;
(g)稳定脂质体膜的足够的电解质;
(h)防止组合物降解的足够的皮肤学上可接受的防腐剂;
(i)0.5-1.5%增稠剂;及
(j)水。
特别优选的组合物是这样的组合物,其中:
炎痛喜康的量为0.4-0.5%;
磷脂的量为15-25%;
胆固醇的量为1.5-4%;
二甲基异山梨糖醇酐的量为3-7%;
四甘醇的量为5-15%;及
增稠剂的量为1.5%。
最优选的组合物基于组合物的总重量按重量计大约包含:
(a)0.5%炎痛喜康;
(b)20%磷脂;
(c)2%胆固醇;
(d)5%二甲基异山梨糖醇酐;
(e)10%四甘醇;
(f)0.06%氢氧化钠和0.1%柠檬酸;
(g)0.1%氯化钠;
(h)0.2%对羟基苯甲酸甲酯、0.02%对羟基苯甲酸丙酯、0.01%丁化羟基甲苯和0.15%乙二胺四乙酸二钠;
(i)1.5%羟丙甲基纤维素;及
(j)水。
本发明的脂质体炎痛喜康制剂优选通过下列步骤制备:
(a)在第一个容器中将磷脂和有机溶剂体系加热到大约60-80℃,优选大约70-75℃,将活性组分溶解于其中,向其中加入辅助配制剂,搅拌混合物使完全溶解;
(b)在第二个容器中将一部分水加热至90-95℃,将防腐剂溶于其中,使混合物冷却,然后加入剩余的辅助配制剂和剩余的水,搅拌混合物使完全溶解;由此制备水相组分;
(c)利用真空将第一个容器中的内容物直接转移到水相组分中,同时用高性能混合装置,特别是高剪切混合器对如此得到的结合物进行匀化;及
(d)利用真空将增稠剂加到所产生的混合物中,同时进一步匀化。
优选地,将水相组分置于可装配匀化器的合适的容器中,在注入有机组分期间通过产生大湍流进行匀化。可以使用任何对混合物施加高剪切力的混合装置或匀化器。通常,可以使用转速能达大约1500-20000rpm、尤其是大约3000至大约6000rpm的混合器。适用于步骤(d)的增稠剂有,例如,黄原胶、羟丙基纤维素、羟丙基甲基纤维素或其混合物,优选纤维素衍生物。增稠剂的用量取决于其他组分的性质和浓度,通常为大约0.5-1.5%,尤其是大约1.5%。
为了防止在制备脂质体制剂过程中所用的物质发生降解,最好用隋性气体如氮或氩气吹洗所有溶液,并在隋性气氛下进行所有步骤。
按上述方法制得的脂质体通常含有的活性组分大部分都结合在脂质双层中,不需要将脂质体与未包封的物质分离。单一双层脂质体可以方便地直接使用或者也可以与其他合适的用于局部给药的可药用载体结合使用。
上述脂质体组合物特别适用于局部治疗软组织损伤和创伤源的病理扭伤患者,尤其是治疗其急性形式。典型的病理疾病是关节如膝关节、踝关节、腕关节、肘关节、肩关节和背关节的损伤。本发明的脂质体组合物能很好地解除轻微疼痛和严重疼痛。含炎痛喜康的组合物需要时可以规则的间隔局部用于所治疗的区域,通常是每天1、2或3次。治疗持续时间取决于所治疗疾病的性质、程度和严重性以及使用组合物的步率。
下述实施例用来具体说明本发明范围内的所有方面,但不是对本发明的限制。
实施例1
组分 量,mg/每克乳油
炎痛喜康 5.0
大豆卵磷脂 200.0
胆固醇 20.0
四甘醇 100.0
二甲基异山梨糖醇酐 50.0
对羟基苯甲酸甲酯 2.0
对羟基苯甲酸丙脂 0.2
丁化羟基甲苯 0.1
乙二胺四乙酸二钠 1.5
氯化钠 1.0
羟丙基甲基纤维素 15.0
氢氧化钠 0.6
柠檬酸 1.0
纯化水,USP 603.6
步骤:
1.将大豆卵磷脂、四甘醇和二甲基异山梨糖醇酐加热至70-75℃。将炎痛喜康、胆固醇和丁化羟基甲苯溶于热的混合物中,搅拌至完全溶解。
2.在一个容器中将大约1/3的水加热至80-95℃,搅拌下将防腐剂对羟基苯甲酸甲酯和对羟基苯甲酸丙酯溶于其中。使该溶液冷却至大约25℃,然后加入乙二胺四乙酸二钠、氯化钠、氢氧化钠和柠檬酸。加入剩余的水,搅拌至完全溶解。
3.利用真空将第1步得到的混合物转移到第2步得到的混合物中,同时用高剪切混合器匀化结合物,得到匀化产品。
4.利用真空向第3步所得混合物中加入羟丙基甲基纤维素,同时用混合器匀化。
匀化器是在大约3000rpm下操作的Silverson高剪切混合器。转移步骤的流速为大约0.5升/分钟。形成了单一双层脂质体。由第4步得到的白色lipogel乳油可方便地装在合适的容器例如管如PVC覆盖的铝管中。
临床实施例
用实施例1的乳油制剂治疗年龄26-38岁的20个病人。所有病人都患有急性软组织损伤和急性创伤源的病理扭伤(关节外风湿病);最经常的病理疾病是膝、踝、肩和背的损伤。治疗持续10天,每天涂两次乳油。
对乳油的临床评价基于这样一些参数如疼痛、肿胀、活动限制和被动移动以及对效果和耐受性的总的评价。
认为对89%的病人得到的结果优良。具体讲,患有轻度和严重疼痛的病人都在治疗后感觉好得多。
所述药物制剂的耐受性非常好。没有病人出现副作用,所有病人都完成了临床试验。
Claims (9)
1、包含炎痛喜康、磷脂、供炎痛喜康和所述磷脂用的溶剂体系、水和常规的辅助配制剂的局部用脂质体制剂,其特征在于所述组合物包含二甲基异山梨糖醇酐和四甘醇作为溶剂体系。
2、根据权利要求1的组合物,其中脂质体是单一双层脂质体。
3、根据权利要求2的组合物,其中磷脂是卵磷脂。
4、根据权利要求3的组合物,其中二甲基异山梨糖醇酐和四甘醇的用量基于组合物的总重量为8-30%(重量)。
5、根据权利要求4的组合物,其中二甲基异山梨糖醇酐的量与四甘醇的量的比率为2∶1-1∶3。
6、根据权利要求1的组合物,其中基于组合物的总重量按重量计包含:
(a)0.1-0.6%炎痛喜康;
(b)10-30%磷脂;
(c)0.5-8%胆固醇;
(d)3-10%二甲基异山梨糖醇酐;
(e)5-20%四甘醇;
(f)保持组合物的pH值在5-7的缓冲剂;
(g)稳定脂质体膜的足够的电解质;
(h)防止组合物降解的足够的皮肤学上可接受的防腐剂;
(i)0.5-1.5%增稠剂;及
(j)水。
7、根据权利要求6的组合物,其中:
炎痛喜康的量为0.4-0.5%;
磷脂的量为15-25%;
胆固醇的量为1.5-4%;
二甲基异山梨糖醇酐的量为3-7%;
四甘醇的量为5-15%;及
增稠剂的量为1.5%。
8、根据权利要求7的组合物,其中包含大约:
(a)0.5%炎痛喜康;
(b)20%磷脂;
(c)2%胆固醇;
(d)5%二甲基异山梨糖醇酐;
(e)10%四甘醇;
(f)0.06%氢氧化钠和0.1%柠檬酸;
(g)0.1%氯化钠;
(h)0.2%对羟基苯甲酸甲酯、0.02%对羟基苯甲酸丙脂、0.01%丁化羟基甲苯和0.15%乙二胺四乙酸二钠;
(i)1.5%羟丙甲基纤维素;及
(j)水。
9、制备权利要求1-8中任一项所要求保护的组合物的方法,其特征在于所述方法包括下列步骤:
(a)在第一个容器中加热磷脂和有机溶剂体系,将活性组分溶解于其中,向其中加入辅助配制剂,搅拌混合物使完全溶解;
(b)在第二个容器中加热一部分水,将防腐剂溶于其中,使混合物冷却,然后加入剩余的辅助配制剂和剩余的水,搅拌混合物使完全溶解;由此制备水相组分;
(c)利用真空将第一个容器中的内容物直接转移到水相组分中,同时用高性能混合器进行匀化;及
(d)利用真空将增稠剂加到所产生的混合物中,同时进一步匀化。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP92200398 | 1992-02-12 | ||
EP92200398 | 1992-02-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1075633A true CN1075633A (zh) | 1993-09-01 |
Family
ID=8210420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN93101515A Pending CN1075633A (zh) | 1992-02-12 | 1993-02-11 | 脂质体炎痛喜康制剂 |
Country Status (13)
Country | Link |
---|---|
US (1) | US5505960A (zh) |
JP (1) | JPH07503952A (zh) |
CN (1) | CN1075633A (zh) |
AT (1) | ATE137959T1 (zh) |
AU (1) | AU661755B2 (zh) |
CA (1) | CA2129624A1 (zh) |
DE (1) | DE69302677T2 (zh) |
DK (1) | DK0625898T3 (zh) |
ES (1) | ES2090966T3 (zh) |
IL (1) | IL104688A0 (zh) |
MX (1) | MX9300707A (zh) |
TW (1) | TW262382B (zh) |
ZA (1) | ZA93954B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101637451B (zh) * | 2009-06-12 | 2011-03-30 | 陶灵刚 | 一种氯诺昔康脂质体药物组合物及其固体制剂 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002085414A2 (en) * | 2000-12-19 | 2002-10-31 | The Board Of Regents Of The University Of Texas System | Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
US20100173876A1 (en) * | 2000-12-19 | 2010-07-08 | The Board Of Regents Of The University Of Texas System | Oil-based nsaid compositions and methods for making and using same |
US20040077604A1 (en) | 2001-12-19 | 2004-04-22 | Lenard Lichtenberger | Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity |
WO2005011708A1 (en) * | 2003-07-31 | 2005-02-10 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers |
EP2010180A4 (en) | 2006-04-21 | 2010-10-13 | Glaxosmithkline Llc | IL-8 RECEPTOR ANTAGONISTS |
US8772358B2 (en) * | 2008-11-12 | 2014-07-08 | Archer Daniels Midland Co. | Lecithin and plasticizer compositions and methods |
US8956600B2 (en) * | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
US8871811B2 (en) | 2011-02-07 | 2014-10-28 | Professional Compounding Centers of America, Ltd | Permeation enhancers for topical formulations |
US8906397B2 (en) | 2011-02-07 | 2014-12-09 | Professional Compounding Centers of America, Ltd | Permeation enhancers for topical formulations |
US20120201871A1 (en) * | 2011-02-07 | 2012-08-09 | Professional Compounding Centers Of America, Ltd. | Permeation enhancers with liposomes for topical formulations |
MX340951B (es) | 2011-09-29 | 2016-07-29 | Plx Pharma Inc | Portadores dependientes del ph para la liberacion dirigida de productos farmaceuticos a lo largo del tracto gastrointestinal, composiciones de los mismos, y fabricación y uso de las mismas. |
US9415054B2 (en) | 2013-06-13 | 2016-08-16 | Professional Compounding Centers Of America (Pcca) | Piroxicam transdermal composition to treat plantar fasciitis |
MX2022011743A (es) | 2020-03-26 | 2022-12-08 | Plx Opco Inc | Portadores farmaceuticos con capacidad de reconstitucion dependiente del ph y metodos para elaborar y usar los mismos. |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3699230A (en) * | 1971-03-12 | 1972-10-17 | Robins Co Inc A H | Dimethylisosorbide solvent for muscle relaxant drugs |
US4082881A (en) * | 1976-12-23 | 1978-04-04 | E. R. Squibb & Sons, Inc. | Topical and other type pharmaceutical formulations containing isosorbide carrier |
DE3532562A1 (de) * | 1985-09-12 | 1987-03-12 | Dolorgiet Gmbh & Co Kg | Transdermal resorbierbare, wasserhaltige zubereitungen von arylpropionsaeurederivaten und verfahren zur herstellung derselben |
DE3778972D1 (de) * | 1986-06-12 | 1992-06-17 | Liposome Co Inc | Mittel unter verwendung liposomverkapselter, nichtsteroider, antiinflammatorischer arzneistoffe. |
AU598002B2 (en) * | 1986-07-15 | 1990-06-14 | Cilag Ltd. | Method of preparing single bilayered liposomes |
SE8603812D0 (sv) * | 1986-09-12 | 1986-09-12 | Draco Ab | Administration of liposomes to mammals |
US4963297A (en) * | 1987-12-22 | 1990-10-16 | The Liposome Company, Inc. | Spontaneous vesticulation of multilamellar liposomes |
BE1000381A4 (fr) * | 1987-03-13 | 1988-11-16 | Pharlyse Sa | Preparation pharmaceutique a base d'indometacine. |
US4783450A (en) * | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
US5169846A (en) * | 1989-10-12 | 1992-12-08 | Crooks Michael J | Non-aqueous micellar solutions of anthelmintic benzimidazoles, closantel, or phenothiazine, and insect growth regulators |
-
1993
- 1993-02-04 JP JP5513755A patent/JPH07503952A/ja active Pending
- 1993-02-04 ES ES93903912T patent/ES2090966T3/es not_active Expired - Lifetime
- 1993-02-04 DK DK93903912.9T patent/DK0625898T3/da active
- 1993-02-04 AT AT93903912T patent/ATE137959T1/de not_active IP Right Cessation
- 1993-02-04 US US08/256,850 patent/US5505960A/en not_active Expired - Fee Related
- 1993-02-04 CA CA002129624A patent/CA2129624A1/en not_active Abandoned
- 1993-02-04 AU AU34950/93A patent/AU661755B2/en not_active Ceased
- 1993-02-04 DE DE69302677T patent/DE69302677T2/de not_active Expired - Fee Related
- 1993-02-10 MX MX9300707A patent/MX9300707A/es unknown
- 1993-02-11 IL IL104688A patent/IL104688A0/xx unknown
- 1993-02-11 CN CN93101515A patent/CN1075633A/zh active Pending
- 1993-02-11 ZA ZA93954A patent/ZA93954B/xx unknown
- 1993-04-10 TW TW082102677A patent/TW262382B/zh active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101637451B (zh) * | 2009-06-12 | 2011-03-30 | 陶灵刚 | 一种氯诺昔康脂质体药物组合物及其固体制剂 |
Also Published As
Publication number | Publication date |
---|---|
AU3495093A (en) | 1993-09-03 |
MX9300707A (es) | 1994-01-31 |
AU661755B2 (en) | 1995-08-03 |
DK0625898T3 (da) | 1996-06-03 |
CA2129624A1 (en) | 1993-08-19 |
DE69302677T2 (de) | 1996-10-02 |
JPH07503952A (ja) | 1995-04-27 |
ES2090966T3 (es) | 1996-10-16 |
US5505960A (en) | 1996-04-09 |
ATE137959T1 (de) | 1996-06-15 |
DE69302677D1 (de) | 1996-06-20 |
IL104688A0 (en) | 1993-06-10 |
TW262382B (zh) | 1995-11-11 |
ZA93954B (en) | 1994-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1263447C (zh) | 还原型辅酶q的稳定溶液 | |
CN1075633A (zh) | 脂质体炎痛喜康制剂 | |
CN1076614A (zh) | 脂质体依太康唑制剂 | |
EP2373346B1 (en) | Ibuprofen for topical administration | |
US4555524A (en) | Transdermal 2-(4-isobutylphenyl)-propionic acid medication and methods | |
CN1266370A (zh) | 活性维生素d3乳状液类型的洗剂 | |
CN1159158A (zh) | 抗菌水包油乳液 | |
EP0733358A2 (de) | Intravenös applizierbare Nanosuspensionen | |
JP2003526595A (ja) | 細胞媒介性免疫病の処置 | |
CN1239427A (zh) | Mupirocin在制备用于治疗与病原生物体鼻咽建群有关的细菌感染的药物中的应用 | |
EP0786993B1 (en) | Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and their use in the treatment of metabolic and cardiovascular disorders | |
CN100341577C (zh) | 经皮吸收制剂 | |
CN1111128A (zh) | 含吡氧噻嗪的皮肤表面抗炎组合物 | |
CN114828840A (zh) | 秋水仙碱的改进的局部用组合物 | |
US5624682A (en) | Pharmaceutical formulations based on a ketoprofen solution in soft capsules, and processes for their preparation | |
EP0841896B1 (en) | Reverse gels comprising a continuous fluorinated phase | |
CN100346773C (zh) | 丙酸氯倍他索的脂质体制剂 | |
EP1156829B1 (fr) | Formulation stable contenant de la fumagilline | |
EP0625898B1 (en) | Liposomal piroxicam formulations | |
JPH085793B2 (ja) | 合成脂質を含んで成る非経腸投与用リポゾーム製剤 | |
JP2747317B2 (ja) | 皮膚の健康を維持または回復する薬剤 | |
JPH09176014A (ja) | 抗真菌性外用組成物 | |
CN1562014A (zh) | 注射用ve烟酸酯乳剂及其制备方法 | |
CN101057845A (zh) | 草乌甲素干乳剂及其制备方法与应用 | |
JPH0368009B2 (zh) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |